# Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

> **NCT00446342** · PHASE1 · COMPLETED · sponsor: **Sunesis Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- B-lymphoid Malignancies
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** SNS-032 Injection

## Key facts

- **NCT ID:** NCT00446342
- **Lead sponsor:** Sunesis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-12
- **Final completion:** 2009-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446342, "Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00446342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*